Overview

AT1R Blockade and Periodic Breathing During Sleep in Hypoxia

Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
Sleep disordered breathing (SDB) is characterized by regular periods of no breathing (apnea) or low levels of breathing (hypopnea) and leads to repeated periods of low oxygenation, termed intermittent hypoxia that causes fluctuations in blood oxygen levels. This leads to increased peripheral chemoreflex sensitivity that is thought to occur through the stimulation of angiotensin-II, type-I receptors (AT1R) that are expressed primarily on glomus cells within the peripheral chemoreflex and ultimately results in long lasting hypertension. The goal of this study is to determine if AT1R receptor blockade can prevent the increase in chemoreflex sensitivity following one night of hypoxia and improve the severity of SDB.
Phase:
Phase 4
Details
Lead Sponsor:
University of British Columbia
Treatments:
Angiotensin Receptor Antagonists
Losartan